Updated Zolgensma data show continued benefit across SMA 1 patients

Novartis unveiled updated data from three studies of Zolgensma to treat spinal muscular atrophy type 1 that continue to show improvements in motor milestones for both presymptomatic and symptomatic patients, as well as maintenance of efficacy for nearly four years. Broadly, the data suggest the one-time treatment's efficacy is on par with marketed SMA drug Spinraza.

The AveXis Inc. unit of Novartis AG (NYSE:NVS; SIX:NOVN) presented data from the SPR1NT, STR1VE and START studies

Read the full 736 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE